摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-di-O-benzyl-D-xylopyranose

中文名称
——
中文别名
——
英文名称
2,4-di-O-benzyl-D-xylopyranose
英文别名
(3R,4S,5R)-3,5-bis(phenylmethoxy)oxane-2,4-diol
2,4-di-O-benzyl-D-xylopyranose化学式
CAS
——
化学式
C19H22O5
mdl
——
分子量
330.381
InChiKey
ITBOGRYSMBQFRV-MHYDHLEJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    24
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    68.2
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Total Synthesis and Structural Revision of the Presumed Aeruginosins 205A and B
    作者:Stephen Hanessian、Xiaotian Wang、Karolina Ersmark、Juan R. Del Valle、Ellen Klegraf
    DOI:10.1021/ol901702k
    日期:2009.9.17
    A stereoselective synthesis of enantiopure aeruginosin 205B aglycon confirms the presence of a (3R,2S)-3-chloroleucine amide residue and a (6R)-hydroxy (4aR,7aS)-octahydroindole-(2S)-2-carboxamide (Choi) subunit instead of a 6-chloro-substituted core (Ccoi). Enzyme inhibitory tests against thrombin revealed an IC50 of 0.31 μM. The total synthesis of the presumed aeruginosin 205B shows that the α-d-xylopyranosyl
    立体选择性合成对映体纯绿蛋白酶205B糖苷配基证实存在(3 R,2 S)-3-酸酰胺残基和(6 R)-羟基(4a R,7a S)-八氢吲哚-(2 S)-2 -羧酰胺(Choi)亚基,而不是6-取代的核心(Ccoi)。酶对凝血酶的抑制试验显示IC 50为0.31μM。推测的绿素酶205B的总合成表明,α- d-木喃糖基单元在C-4'处(而不是在C-3'处)具有硫酸根基团。NMR数据的比较导致了绿素205A的相同修订。
  • Synthesis and Structure Verification of the Vaccine Adjuvant QS-7-Api. Synthetic Access to Homogeneous <i>Quillaja saponaria</i> Immunostimulants
    作者:Kai Deng、Michelle M. Adams、David Y. Gin
    DOI:10.1021/ja801008m
    日期:2008.5.1
    is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccine clinical trials. Tedious isolation/purification protocols and uncertainty in its structural constitution have hindered the clinical development of QS-7. A chemical synthesis of QS-7-Api is described, providing structural verification of the adjuvant. A novel semisynthetic
    QS-7-Api 是一种非常有效的免疫佐剂,从皂荚树的树皮中分离出来。它的毒性明显低于 QS-21,一种相关的皂苷,目前是抗癌和抗病毒疫苗临床试验中的首选佐剂。繁琐的分离/纯化方案及其结构构成的不确定性阻碍了 QS-7 的临床开发。描述了 QS-7-Api 的化学合成,提供了佐剂的结构验证。还建立了 QS-7-Api 的新型半合成序列,极大地促进了 QS-7 的临床前和临床评估。
  • [EN] TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF<br/>[FR] SAPONINES TRITERPÉNIQUES, PROCÉDÉS DE SYNTHÈSE ET UTILISATIONS DE CELLES-CI
    申请人:SLOAN KETTERING INST CANCER
    公开号:WO2009126737A3
    公开(公告)日:2010-01-14
  • Synthetic Studies of Complex Immunostimulants from <i>Quillaja saponaria</i>:  Synthesis of the Potent Clinical Immunoadjuvant QS-21A<sub>a</sub><sub>pi</sub>
    作者:Yong-Jae Kim、Pengfei Wang、Mauricio Navarro-Villalobos、Bridget D. Rohde、DerryBerry、David Y. Gin
    DOI:10.1021/ja062364i
    日期:2006.9.1
    QS-21 is one of the most promising new adjuvants for immune response potentiation and dose-sparing in vaccine therapy given its exceedingly high level of potency and its favorable toxicity profile. Melanoma, breast cancer, small cell lung cancer, prostate cancer, HIV-1, and malaria are among the numerous maladies targeted in more than 80 recent and ongoing vaccine therapy clinical trials involving QS-21 as a critical adjuvant component for immune response augmentation. QS-21 is a natural product immunostimulatory adjuvant, eliciting both T-cell- and antibody-mediated immune responses with microgram doses. Herein is reported the synthesis of QS-21A(api) in a highly modular strategy, applying novel glycosylation methodologies to a convergent construction of the potent saponin immunostimulant. The chemical synthesis of QS-21 offers unique opportunities to probe its mode of biological action through the preparation of otherwise unattainable nonnatural saponin analogues.
  • Synthesis of the Potent Immunostimulatory Adjuvant QS-21A
    作者:Pengfei Wang、Yong-Jae Kim、Mauricio Navarro-Villalobos、Bridget D. Rohde、David Y. Gin
    DOI:10.1021/ja0422007
    日期:2005.3.1
    QS-21A is one of the most promising new adjuvants for immune response potentiation and dose-sparing in vaccine therapy, given its exceedingly high level of potency and its favorable toxicity profile. Melanoma, breast cancer, small cell lung cancer, prostate cancer, HIV-1, and malaria are among the numerous maladies targeted in more than 80 recent and ongoing clinical trials involving QS-21A as a critical component for immune response augmentation in microgram doses. Herein is reported the first synthesis and structure verification of QS-21Aapi, applying novel glycosylation methodologies in the convergent modular construction of this rare and potent natural product immunostimulant.
查看更多